Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BOTOX Efficacy and Safety in the Treatment of Knee Osteoarthritis
2014-001076-58Phase 2Completed
- Sponsor
- Allergan
- Start
- Oct 2014
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of botulinum toxin type A in knee osteoarthritis (OA) (3 arms), sponsored by Allergan. Primary endpoint: Change from baseline of the 7-day average of the daily pain score. Started Oct 2014; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
knee osteoarthritis (OA)
Beyond the preview
Go deeper on 2014-001076-58.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001076-58.